Abstract:Accumulating evidence suggests that tumor-infiltrating immune cells (TICs) in the tumor microenvironment (TME) serve as promising therapeutic targets. CXCL8 (IL-8) may also be a potential therapeutic target in cancer. CXCL8 is a potent chemotactic factor for neutrophils, myeloid-derived suppressor cells (MDSCs) and monocytes, which are considered immunosuppressive components in cancer-bearing hosts. Here, we identified the TME-related gene CXCL8 in a high-ImmuneScore population that contributed to better survival in colorectal cancer (CRC) patients from The Cancer Genome Atlas (TCGA) database. An integrated gene profile and functional analysis of TIC proportions revealed that the dendritic cell (DC) activation markers CD80, CD83, and CD86 were positively correlated with CXCL8 expression, suggesting that CXCL8 may be functional as antitumor immune response status in the TME. The gene signature was further validated in independent GSE14333 and GSE38832 cohorts from the Gene Expression Omnibus (GEO). To test the differential contributions of immune and tumor components to progression, three CRC cell lines, CT26, MC38 and HCT116, were used. In vitro results suggested no significant growth or survival changes following treatment with an inhibitor of the CXCL8 receptor (CXCR1/2) such as reparixin or danirixin. In vivo treatment with danirixin (antagonists of CXCR2) promoted tumor progression in animal models established with CT26 cells. CXCR2 antagonism may function via an immune component, with CXCR2 antagonist treatment in mice resulting in reduced activated DCs and correlating with decreased Interferon gamma (IFN-γ) or Granzyme B expressed CD8+ T cells. Furthermore, CXCL8 induced DC migration in transwell migration assays. Taken together, our data suggested that targeting the CXCL8-CXCR2 axis might impede DC activation or recruitment, and this axis could be considered a favorable factor rather than a target for critical antitumor effects on CRC.

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

CXCL8 in Tumor Biology and Its Implications for Clinical Translation

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer

Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

The CXCL8-CXCR1/2 pathways in cancer

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment

CX3CR1+CD8+ T cells: Key players in antitumor immunity

Potential Roles and Targeted Therapy of the CXCLs/CXCR2 Axis in Cancer and Inflammatory Diseases

Regulative Role of the CXCL13-CXCR5 Axis in the Tumor Microenvironment

The role of CXCL12 in tumor microenvironment

Role of chemokines in the crosstalk between tumor and tumor-associated macrophages

Chronic inflammation, cancer development and immunotherapy

CXCL12 Signaling in the Tumor Microenvironment

CXCL8 induces M2 macrophage polarization and inhibits CD8+ T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer

Role of tumor microenvironment in cancer progression and therapeutic strategy